Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

被引：26

作者：

Syriac, Arun Kadamkulam ^{[1
]}

Nandu, Nitish Singh ^{[2
]}

Leone, Jose Pablo ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Hosp & Palliat Med, Bronx, NY 10467 USA

来源：

BREAST CANCER-TARGETS AND THERAPY | 2022年 / 14卷

关键词：

triple-negative breast cancer; metastatic disease; brain metastasis; prognosis clinical outcomes; immunotherapy; stereotactic radiosurgery; whole-brain radiation therapy; antibody-drug conjugate; oligometastatic brain metastasis; clinical outcomes; prediction; prognosis; personalization; multi-omics; machine learning; individualized treatment algorithms; patient benefits; WHOLE-BRAIN RADIOTHERAPY; GRADED PROGNOSTIC ASSESSMENT; PHASE-III TRIAL; FRONT-LINE CHEMOTHERAPY; CELL LUNG-CARCINOMA; SACITUZUMAB GOVITECAN; SURGICAL RESECTION; MALIGNANT-MELANOMA; DOUBLE-BLIND; CAPECITABINE;

D O I：

10.2147/BCTT.S274514

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It is estimated that approximately one-third of patients with triple-negative breast cancer (TNBC) will develop brain metastases. The prognosis for patients with breast cancer brain metastasis has improved in the recent past, especially for hormone receptor and human epidermal growth factor receptor 2 (HER) positive subtypes. However, the overall survival rate for patients with triple-negative subtype remains poor. The development of newer treatment options, including antibody-drug conjugates such as Sacituzumab govitecan, is particularly encouraging. This article reviews the clinical outcomes, challenges, and current approach to the treatment of brain metastasis in TNBC. We have also briefly discussed newer treatment options and ongoing clinical trials. The development of brain metastasis significantly decreases the quality of life of patients with TNBC, and newer treatment strategies and therapeutics are the need of the hour for this disease subgroup.

引用

页码：1 / 13

页数：13

共 50 条

[1] Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic
Zimmer, Alexandra S.
CANCER JOURNAL, 2021, 27 (01): : 76 - 82
[2] Central nervous system metastases in triple-negative breast cancer: A step in the right direction
Shreenivas, Aditya
Shapiro, Charles L.
BREAST JOURNAL, 2019, 25 (03): : 361 - 362
[3] Proteomics of triple negative breast cancer developing metastases to central nervous system
Rojas, K.
Trilla-Fuertes, L.
Gamez, A.
Sepulveda Sanchez, J.
Manso Sanchez, L.
Prado-Vasquez, G.
Chiva, C.
Zapater-Moros, A.
Llorente-Armijo, S.
Mendiola, D. C.
Sabido, E.
Fresno, J. A.
Ciruelos Gil, E. M.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2017, 28
[4] Triple-Negative Breast Cancer: Current Data and Future Prospects
de Nonneville, A.
Goncalves, A.
ONCOLOGIE, 2019, 21 (1-4) : 33 - 39
[5] Triple-Negative Breast Cancer: Current Practice and Future Directions
Costa, Ricardo L. B.
Gradishar, William J.
JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (05) : 301 - +
[6] Triple-negative breast cancer: current management and future options
Conte, PierFranco
Guarneri, Valentina
EJC SUPPLEMENTS, 2009, 7 (01): : 14 - 18
[7] Current landscape of personalized clinical treatments for triple-negative breast cancer
Zhang, Jun
Xia, Yu
Zhou, Xiaomei
Yu, Honghao
Tan, Yufang
Du, Yaying
Zhang, Qi
Wu, Yiping
FRONTIERS IN PHARMACOLOGY, 2022, 13
[8] Triple-negative Breast Cancer and Brain Metastases
Sait, B.
Cinar, E.
Altundag, K.
CLINICAL ONCOLOGY, 2010, 22 (01) : 84 - 84
[9] Locoregional treatments for triple-negative breast cancer
Eiermann, W.
Vallis, K. A.
ANNALS OF ONCOLOGY, 2012, 23 : 30 - 34
[10] Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases
Rojas Laimito, Katerin
Gamez-Pozo, Angelo
Sepulveda, Juan
Manso, Luis
Lopez-Vacas, Rocio
Pascual, Tomas
Fresno Vara, Juan A.
Ciruelos, Eva
ECANCERMEDICALSCIENCE, 2016, 10

← 1 2 3 4 5 →